Premium
P2‐492: DIAGNOSTIC UTILITY OF NIH TOOLBOX COGNITION BATTERY IN OLDER ADULTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT
Author(s) -
Hill-Jarrett Tanisha G.,
Garcia Sarah,
Shair Sarah,
Kavcic Voyko,
Bhaumik Arijit K.,
Rose Edna,
Teboe Sherry,
Campbell Stephen,
Lichtenberg Peter,
Hampstead Benjamin M.,
Giordani Bruno
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1185
Subject(s) - audiology , cognition , neuropsychology , episodic memory , cognitive test , cognitive impairment , medicine , psychology , psychiatry
CogState Brief Battery and the Auditory Verbal Learning Test (AVLT). Using the ATN (amyloid, tau, and neurodegeneration/ neuronal injury) framework, we focused on a subset of biomarker positive individuals we hypothesized are most likely to demonstrate subtle cognitive dysfunction. Biomarker positive subjects (n 1⁄4 29, A+T+Nor A+T+N+; median age 1⁄4 79.5, range 65-87; percent male 1⁄4 65.5) were older than biomarker negative subjects (n 1⁄4 47 A-T-N-; median age 1⁄4 61.3, range 1⁄4 50-83; percent male 1⁄4 44.7); groups did not significantly differ on gender or education. Subtle cognitive dysfunction was defined as performance -1SD on the CogState Learning/Working Memory Composite using age-corrected normative data provided by CogState and age-corrected published normative scores for AVLT 30-minute delayed recall (Ivnik et al., 1992 TCN). Results:Biomarker positive subjects showed a higher frequency of subtle cognitive dysfunction (15.4%) relative to biomarker negative subjects (2.2%) on the CogState Learning/WorkingMemory Composite (c1⁄4 4.49, p1⁄4 .05), particularly on One Card Learning accuracy that contributes to this composite score (c 1⁄4 5.27, p 1⁄4 .02; biomarker positive 23.1%, biomarker negative 4.3%). The frequency of subtle cognitive dysfunction on the AVLT 30-minute delayed recall was comparable across groups (p> .99; biomarker positive 19.2%, biomarker negative 17.0%). Conclusions:Cognitively unimpaired biomarker positive participants showed a higher frequency of subtle cognitive dysfunction on select CogState measures relative to biomarker negative subjects, although the frequency of subtle cognitive dysfunction was low. Further investigation of subtle cognitive dysfunction in preclinical Alzheimer’s disease may be useful for predicting biomarker status among CU adults.